Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.

AI-supported mammography screening significantly increases breast cancer detection rates while maintaining comparable recall ...

In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their ...

Study reveals short term safety of active monitoring for ductal carcinoma in situ. ScienceDaily . Retrieved January 5, 2025 from www.sciencedaily.com / releases / 2024 / 12 / 241212115836.htm ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

Women with Stage 0 breast cancer who got biannual mammograms and delayed surgery for two years fared as well as those who got immediate surgery.

Early results from a clinical trial appear to confirm that most women with the precancerous breast condition known as ductal ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common ...

BOSTON & MONTREAL, December 30, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...